Evidence map›Paper›PMID 31930543›Full record

ArticleVox sanguinis2020

Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.

Markus Eickmann, Ute Gravemann, Wiebke Handke, Frank Tolksdorf, Stefan Reichenberg, Thomas H Müller, Axel Seltsam

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vox sanguinis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 80 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04619290 phase1unknown statusnot on this map

Treatment in Outpatient Patients With Covid-19 With Methylene Blue and Photodynamic

TypeinterventionalSponsorHospital Reg. Lic. Adolfo Lopez MateosRan2020 to 2020Enrolled46ConditionsSars Cov 2ArmsSublingual Methylene blue, Control patients
NCT04642326 naunknown statusnot on this map

Prospective, Parallel, Multicenter Randomized Controlled Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis

TypeinterventionalSponsorRD Global Araştirma Geliştirme Sağlik Ilaç Inşaat Yatirimlari A.Ş.Ran2020 to 2021Enrolled50ConditionsCovid19ArmsTest Group: experimental - UVC Therapy applied
3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Consolidating food safety measures against COVID-19.The Journal of the Egyptian Public Health Association · 2022
    Review
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Markus EickmannInstitute for Virology, Philipps University Marburg, Marburg, Germany.
Ute GravemannGerman Red Cross Blood Service NSTOB, Springe, Germany.
Wiebke HandkeGerman Red Cross Blood Service NSTOB, Springe, Germany.
Frank TolksdorfMaco Pharma International GmbH, Langen, Germany.
Stefan ReichenbergMaco Pharma International GmbH, Langen, Germany.
Thomas H MüllerGerman Red Cross Blood Service NSTOB, Springe, Germany.
Axel SeltsamGerman Red Cross Blood Service NSTOB, Springe, Germany.ORCID https://orcid.org/0000-0001-5858-5097
German Red Cross · DEPhilipps University of Marburg · DE

Funding

German Red Cross Blood Services (Deutsche Forschungsgemeinschaft der Blutspendedienste des Deutschen Roten Kreuzes)Macopharma S.A.S.
6 · The paper itself

Abstract

backgroundEmerging viruses like severe acute respiratory syndrome coronavirus (SARS-CoV), Crimean-Congo haemorrhagic fever virus (CCHFV) and Nipah virus (NiV) have been identified to pose a potential threat to transfusion safety. In this study, the ability of the THERAFLEX UV-Platelets and THERAFLEX MB-Plasma pathogen inactivation systems to inactivate these viruses in platelet concentrates and plasma, respectively, was investigated. MATERIALS AND

methodsBlood products were spiked with SARS-CoV, CCHFV or NiV, and then treated with increasing doses of UVC light (THERAFLEX UV-Platelets) or with methylene blue (MB) plus increasing doses of visible light (MB/light; THERAFLEX MB-Plasma). Samples were taken before and after treatment with each illumination dose and tested for residual infectivity.

resultsTreatment with half to three-fourths of the full UVC dose (0·2 J/cm

conclusionOur study demonstrates that both THERAFLEX UV-Platelets (UVC) and THERAFLEX MB-Plasma (MB/light) effectively reduce the infectivity of SARS-CoV, CCHFV and NiV in platelet concentrates and plasma, respectively.

Indexed as

LightUltraviolet RaysVirus InactivationBlood PlateletsBlood TransfusionHemorrhagic Fever Virus, Crimean-CongoHumansMethylene BlueNipah VirusPlasmaSevere acute respiratory syndrome-related coronavirusMethylene Bluemethylene bluepathogen inactivationplasmaplatelet concentratesultraviolet light

Identifiers

PMID31930543
PMCPMC7169309
OpenAlexW3000244297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.